The concept of platinum sensitivity could be applied to recurrent cervical cancer: a multi-institutional retrospective study from the Japanese Gynecologic Oncology Group

Takekuma, Munetaka; Mori, Keita; Iida, Takuya; Kurihara, Kazuko; Saitou, Motoaki; Tokunaga, Hideki; Kawana, Kei; Ikeda, Masae; Saito, Toshiaki; Miyagi, Etsuko; Nagai, Yutaka; Furusawa, Akiko; Kawano, Yoshiaki; Kawano, Keiichi; Tabata, Tsutomu; Ota, Yoshiyuki; Hayase, Ryoji; Mikami, Mikio; Sugiyama, Toru

doi:10.1007/s00280-017-3402-x

Cited by 7 publications

(9 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, chemotherapy alone did not demonstrate significant survival benefits for local recurrence in our study. Some authors have even promoted the concept of platinum sensitivity in recurrent cervical cancer (23). However, patients eligible to receive third-line chemotherapy for recurrent cervical cancer can expect minimal benefits at the cost of significant toxicity (24).…”

Section: Discussionmentioning

confidence: 99%

Selection of Treatment Regimens for Recurrent Cervical Cancer

Chao

Song

et al. 2021

Front. Oncol.

View full text Add to dashboard Cite

ObjectiveThe selection of individualized treatment for recurrent cervical cancer is challenging. This study aimed to investigate the impact of various therapies on survival outcomes after recurrence.MethodsEligible patients were diagnosed with recurrent cervical cancer between March 2012 and April 2018. Postrecurrence progression-free survival (PFS) and overall survival (OS) were investigated in the whole cohort and in subgroups, categorized by recurrence site and prior radiotherapy history, using a multivariate model that incorporated treatment for primary and recurrent tumors, histological pathology, and FIGO staging.ResultsTwo hundred and sixty recurrent cervical cancer patients were included. As of March 1, 2020, the median postrecurrence PFS and OS were 7.0 (range 0-94) and 24.0 (1.8-149.1) months, respectively. In a multivariate model measured by PFS, radiotherapy was superior to other therapies for the whole cohort (p=0.029) and recurrence only within the pelvic cavity (p=0.005), but the advantages of radiotherapy disappeared in patients with a history of radiotherapy (p values >0.05). For recurrence only beyond the pelvic cavity, combination therapy resulted in improved PFS (p=0.028). For recurrence both within and beyond the pelvic cavity, no therapy regimen provided additional PFS benefits (p values >0.05). Radiotherapy and combination therapy were also associated with improved postrecurrence OS for recurrence within the pelvic cavity (p=0.034) and only beyond the pelvic cavity (p=0.017), respectively.ConclusionsIn cervical cancer patients, postrecurrence radiotherapy can improve PFS and OS for patients with recurrence within the pelvic cavity and without prior radiotherapy. For recurrence beyond the pelvic cavity or cases with a history of radiotherapy, combination or individualized therapy may provide potential survival benefits.

show abstract

Section: Discussionmentioning

confidence: 99%

Selection of Treatment Regimens for Recurrent Cervical Cancer

Chao

Song

et al. 2021

Front. Oncol.

View full text Add to dashboard Cite

show abstract

“…Platinum sensitivity is a well-reported powerful prognostic factor for recurrent ovarian cancer [12]. However, its prognostic value in terms of recurrence pattern [11,13], survival, independent prognostic factors, and clinical implications has been poorly studied for CC [14][15][16][17]. The most relevant study in this setting was conducted by Takekuma et al [15] in 677 patients with CC from 71 centres in Japan.…”

Section: Discussionmentioning

confidence: 99%

“…In this setting, Tanioka et al previously showed that a time to recurrence of 12 months was an independent predictive factor of tumour response, and that a 6 month PFI was an independent prognostic factor of OS for patients with recurrent CC [16]. Takekuma et al suggested that a PFI of 12 months significantly influenced both progression-free survival and OS [14], and that the best cut-off value of PFI that affected OS was 7 months as calculated by the minimum p-value method [15]. In the study of Matoda et al including women with metastatic and recurrent CC, a PFI of more than 24 months was the discriminating point between platinum-sensitive and resistant patients [17,18].…”

Section: Discussionmentioning

confidence: 99%

Recurrence Pattern of Cervical Cancer Based on the Platinum Sensitivity Concept: A Multi-Institutional Study from the FRANCOGYN Group

Foucher

Hennebert

Dabi

et al. 2020

JCM

View full text Add to dashboard Cite

The standard of care for patients with advanced cervical cancer (ACC) includes platinum-based chemotherapy. The concept of platinum sensitivity is a major prognostic factor for patients with ovarian cancer. The aim of this study was to validate the applicability of the platinum sensitivity concept to ACC patients, and to estimate its prognostic interest in terms of overall survival (OS) and pattern of recurrence (location, timing). Data of women with histologically proven FIGO 2019 stages IB3–IV ACC, treated between May 2000 and November 2017 with platinum-based regimens, were retrospectively abstracted from 12 institutions from the FRANCOGYN Group. Respective 3-year OSs were 52% (95% CI: 40.8%–66.8%), 21.6% (95% CI: 12.6%–37.2%), and 14.6% (95% CI: 4.2%–50.2%), in case of recurrence <6 months, between 6 and 17 months, and ≥18 months (p < 0.001). Risk of metastatic or multisite recurrence was significantly higher in case of recurrence <6 months, and risk of local or isolated infradiaphragmatic nodal recurrence was significantly higher in case of recurrence >18 months (p < 0.001). In multivariate analysis, platinum sensitivity status was a strong prognostic factor for OS after recurrence, independent of histological grade, lympho-vascular space involvement, final lymph node status, and treatment. Platinum sensitivity status may help to classify patients in three prognostic subgroups for OS after recurrence, and appears to be a strong prognostic factor correlated to the pattern of recurrence.

show abstract

“…However, if this first-line treatment fails, there is no standard treatment for second-line chemotherapy. In particular, patients who relapse within a short period after treatment with platinum-based agents do not respond well to re-administration of platinum-based agents, with relapse occurring within 12 months according to Moore's criteria ( Tewari et al, 2015 ) and less than 7 months according to Takekuma et al (2017) . The objective of second-line chemotherapy is to palliate symptoms and improve quality of life.…”

Section: Introductionmentioning

confidence: 99%

Metronomic chemotherapy using oral cyclophosphamide and bevacizumab for recurrent cervical cancer: A multi-institutional retrospective study

Isono-Taniguchi

Goto

Takimoto

et al. 2022

Gynecologic Oncology Reports

View full text Add to dashboard Cite

The concept of platinum sensitivity could be applied to recurrent cervical cancer: a multi-institutional retrospective study from the Japanese Gynecologic Oncology Group

Abstract: This study showed that the concept of platinum sensitivity could be applied to recurrent cervical cancer and PFI could be one of the independent prognostic factors for patients with recurrent cervical cancer who have previously been treated with platinum-based chemotherapy.

Cited by 7 publications

References 18 publications

Selection of Treatment Regimens for Recurrent Cervical Cancer

Selection of Treatment Regimens for Recurrent Cervical Cancer

Recurrence Pattern of Cervical Cancer Based on the Platinum Sensitivity Concept: A Multi-Institutional Study from the FRANCOGYN Group

Metronomic chemotherapy using oral cyclophosphamide and bevacizumab for recurrent cervical cancer: A multi-institutional retrospective study

Contact Info

Product

Resources

About